JNJ Price Prediction Next Week
Based on the provided data and recent market developments, here's a comprehensive analysis for JNJ's price movement in the next trading week:
Technical Analysis
The technical indicators show JNJ is currently in a neutral-bearish territory:
- RSI at 51.30 indicates neutral momentum
- MACD at -0.36 suggests bearish momentum
- Current price is trading below both SMA-200 ($151.97) and SMA-20 ($145.14)
- Fibonacci levels indicate key resistance at $148.24 and support at $141.99
Fundamental Catalysts
- Q4 2024 results exceeded expectations with EPS of $2.04 vs consensus of $2.01
- Revenue reached $22.52 billion, up 5.3% year-over-year
- MedTech division faces near-term challenges but expected to rebound in H2 2025
- Recent acquisition of Intra-Cellular Therapies for $14.6B could impact 2025 earnings
Key Price Drivers for Next Week
- Stelara Competition Impact:
- Biosimilar competition in both US and Europe markets
- Expected significant revenue decline from $11B annual sales
- MedTech Concerns:
- Temporary pause of Varipulse device due to safety concerns
- Continued pressure from China's volume-based procurement policies
Price Prediction Based on technical and fundamental analysis:
- Resistance: $148.24 (Fibonacci R1)
- Support: $141.99 (Fibonacci S1)
- Target Range: $143-146
Trading Recommendation: HOLD
- Current challenges with Stelara competition and MedTech division suggest limited upside
- However, strong Q4 results and potential MedTech rebound in H2 2025 provide support
- Wait for clearer technical signals or positive catalysts before initiating new positions
JNJ Similar Chart Price Prediction
The price of JNJ is predicted to go up 2.14%, based on the high correlation periods with DOW. The similarity of these two price pattern on the periods is 94.15%.
JNJ
DOW
Up: 2.14%Similarity: 94.15%
JNJ Revenue Forecast
JNJ EPS Forecast
JNJ FAQs
What is bull’s view on JNJ?
What is bear's view on JNJ?
What is JNJ revenue forecast for next quarter？
What is JNJ eps forecast for next quarter？
JNJ VS S&P500
The majority of J&J's near-term patent losses are for products that are hard to manufacture, which should reduce the intensity of generic competition.
Diverse healthcare segments help insulate J&J from downturns in the overall economy, offering a defensive growth opportunity with a steady and likely growing dividend.
Several of J&J's key next-generation pipeline drugs are specialty drugs that tend to carry strong pricing power as well as lower regulatory hurdles for approval.
JNJ Analyst's Forecast
Terence Flynn
Morgan Stanley
Hold
Price Target
$175 → $163
Upside
+11.16%
Morgan Stanley lowered the firm's price target on Johnson & Johnson to $163 from $175 and keeps an Equal Weight rating on the shares following what the firm views as "generally in line" 2025 guidance. After the Q4 report, the firm made a number of adjustments to its model, noting that J&J expects a more pronounced impact from new product cycles as the year progresses and pointed to Rybrevant plus Lazcluze in NSCLC and Tremfya in IBD as two key drivers.
Rick Wise
Stifel
Hold
Price Target
$170 → $155
Upside
+5.7%
Larry Biegelsen
Wells Fargo
Hold
Price Target
$166 → $152
Upside
+3.66%